Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Harnessing natural killer cells to combat chemotherapy resistance

Project description

Overcoming chemoresistance in breast cancer

Natural killer (NK) cells are key effectors of the innate immune system, capable of destroying cancer cells without prior sensitisation. However, tumours that become resistant to chemotherapy often evade NK cell surveillance. Understanding and reversing this immune evasion is critical for improving outcomes in aggressive cancers like triple-negative breast cancer (TNBC). With the support of the Marie Skłodowska-Curie Actions programme, the NatK project aims to investigate how NK cell function is altered in chemoresistant TNBC. To identify immune-related signatures of resistance, researchers will use spatial transcriptomics and patient-derived organoids. They also plan to enhance NK cytotoxicity through gene-targeted interventions and combine it with chemotherapy to target chemoresistant TNBC.

Objective

Chemotherapy resistance remains a major challenge in cancer treatment, often leading to poor patient outcomes. NatK aims to (1) identify predictive signature of chemoresistance and (2) develop innovative therapeutic strategies to overcome it, using triple negative breast cancer (TNBC) as a model. The focus is on natural killer (NK) cells, hypothesising that reactivating these cells could enhance their cytotoxicity against chemoresistant tumours.

State-of-the-art 10X Visium spatial transcriptomics will be employed to analyse primary TNBC samples from chemotherapy responders and non-responders, mapping NK cell infiltration and activity within the tumour microenvironment (TME). Advanced bioinformatics will identify immune-related signatures of chemoresistance, validated in independent patient cohorts to develop a robust NK cell-related biomarker for patient stratification.

To translate these findings into therapeutic strategies, specific genes upregulated in chemoresistant tumours will be targeted to enhance NK cell-mediated cytotoxicity. Co-culture systems with NK cells and patient-derived organoids will be used to evaluate the impact of gene modulation, followed by the development of small molecule inhibitors targeting promising candidates. The efficacy of combining NK cell activation with chemotherapy will then be assessed both in vitro and in vivo, aiming to establish a novel combination therapy to combat chemoresistance.

NatK integrates state-of-the-art spatial transcriptomics, functional immune profiling and patient-derived organoid models to elucidate chemoresistance mechanisms. The insights gained may have broader implications, potentially extending to other cancer types and guiding targeted immunotherapy development. In line with the MSCA Postdoctoral Fellowship objectives, this interdisciplinary research will advance expertise in cutting-edge biomedical technologies, foster international collaboration, and contribute to advancing oncology in Europe.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-PF-01

See all projects funded under this call

Coordinator

UNIVERSITY OF BRISTOL
Net EU contribution
€ 276 187,92
Address
BEACON HOUSE QUEENS ROAD
BS8 1QU BRISTOL
United Kingdom
Region
South West (England) Gloucestershire, Wiltshire and Bristol/Bath area Bristol, City of
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data